{"id":"CU25187","slug":"extracellular-vesicles--CU25187","source":{"id":"CU25187","dataset":"techtransfer","title":"Extracellular vesicles isolation for lung and liver disease biomarkers","description_":"<p>This technology is a method to purify lung or liver-derived extracellular vesicles as a biomarker for disease, bypassing the need for invasive biopsies directly from these tissues.</p>\r\r<h2>Unmet Need: Minimally invasive biopsies for lung or liver disease</h2>\r\r<p>Biopsies are crucial for diagnosing many diseases, but obtaining tissue samples from internal organs such as the lungs or livers is often difficult and invasive. One possible way to mitigate the invasiveness of these procedures would be to take blood samples, as most organs leave signals of their function in the bloodstream. However, the high heterogeneity of signals from different organs in blood creates substantial noise that complicates isolation and identification of tissue-specific biomarkers. As a result, there is a need for minimally invasive approaches that enable tissue-specific monitoring of disease progression and therapeutic response.</p>\r\r<h2>The Technology: Minimally invasive liquid biopsies for lung or liver disease</h2>\r\r<p>This technology provides a method to isolate and purify extracellular vesicles released by lung alveolar type 1 cells or liver hepatocytes to identify tissue-specific biomarkers in the bloodstream. Following immunoaffinity purification, extracellular vesicle cargos are analyzed for diagnostics, prognostics, or analyses of therapeutic response biomarkers. By using blood-based ‘liquid biopsy’, this approach offers a less invasive alternative to conventional lung and liver biopsies.</p>\r\r<p>This technology has been validated in vitro using blood or serum samples.</p>\r\r<h2>Applications:</h2>\r\r<ul>\r<li>Liquid biopsy of lung or liver</li>\r<li>In vitro assay for lung or liver drug screening</li>\r<li>Diagnostic tool for lung or liver disease</li>\r<li>Prognostic tool for lung or liver disease</li>\r<li>Research model for organ-specific signaling in the bloodstream</li>\r<li>Research model for extracellular vesicle signaling</li>\r</ul>\r\r<h2>Advantages:</h2>\r\r<ul>\r<li>Minimally invasive biopsies for lung or liver</li>\r<li>Isolation of lung or liver signaling in bloodstream</li>\r<li>Provides cell-type-specificity in isolating signals</li>\r</ul>\r\r<h2>Lead Inventor:</h2>\r\r<p><a href=\"https://www.publichealth.columbia.edu/profile/haotian-howie-wu-phd\">Haotian Wu, Ph.D.</a></p>\r\r<h2>Patent Information:</h2>\r\r<p>Patent Pending</p>\r\r<h2>Related Publications:</h2>\r\r<ul>\r<li><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12856775/\">Pierri B, Eitan E, Witwer KW, Re DB, Baccarelli AA, Wu H. “Tissue-Specific Extracellular Vesicles Enriched From Circulation: Exploring the Liquid Biopsy Perspective” J Extracell Biol. 2026 Jan 30;5(2):e70106.</a></li>\r</ul>\r\r<h2>Tech Ventures Reference:</h2>\r\r<ul>\r<li><p>IR CU25187</p></li>\r<li><p>Licensing Contact: <a href=\"mailto:techtransfer@columbia.edu\">Joan Martinez</a></p></li>\r</ul>","tags":[],"file_number":"CU25187","collections":[],"meta_description":"Minimally invasive blood test isolates lung/liver–specific extracellular vesicles for tissue biomarkers and disease monitoring.","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":4.0,\"readiness\":3.0,\"scalability\":3.0,\"timeliness\":3.0},\"weighted_score\":3.55,\"risks\":[\"Cell-type specific vesicle isolation from blood may face low_abundance and technical variability; clinical validation required beyond in vitro.\",\"Regulatory/commercial pathway unclear for biomarker assays; scalability of immunoaffinity purification at highThroughput needs demonstration.\",\"Potential competition from existing liquid biopsy approaches; need clear regulatory pathway for diagnostic use.\",\"IP landscape unclear beyond ongoing patent activity; freedom-to-operate risks if related methods exist.\"],\"one_sentence_take\":\"Novel cell-type-specific extracellular vesicle isolation for liquid biopsy shows solid novelty and impact potential, but readiness and scalability require validation in clinical settings and supporting IP clarity.\"}","inventors":["Andrea Baccarelli MD, PhD","Biancamaria Pierri","Gabriela L. Jackson","Haotian Wu"],"manager":"Joan Martinez","depts":["Environmental Health Science","Mailman School Of Public Health (MSPH)"],"divs":["Mailman School Of Public Health (MSPH)"],"date_released":"2026-05-21"},"highlight":{},"matched_queries":null,"score":0.0}